United States-based Titan Pharmaceuticals Inc. (NASDAQ: TTNP) announced yesterday its financial results for the second quarter ended 30 June 2019.
The company reported around USD0.5m in revenues for the three months ended 30 June 2019 compared with revenues of around USD2.7m in the year-ago period.
The firm posted total operating expenses for the second quarter of 2019 at around USD5.4m compared with around USD3.3m in the same period in 2018.
Net loss applicable to common shareholders in the second quarter of 2019 was approximately USD5.2m, or approximately USD0.38 per share, compared with a net loss applicable to common shareholders of approximately USD0.9m, or approximately USD0.25 per share, in the same quarter in 2018.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva